Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient

BACKGROUND: Autoimmune adverse events are the most relevant risks of alemtuzumab therapy. We present a patient with relapsing-remitting multiple sclerosis, who developed adult-onset Still’s disease (AOSD) following alemtuzumab treatment. CASE PRESENTATION: The patient suffered from sore throat, swal...

Descripción completa

Detalles Bibliográficos
Autores principales: Krämer, Julia, Krömer-Olbrisch, Tanja, Lakomek, Heinz-Jürgen, Schellinger, Peter D., Foell, Dirk, Meuth, Sven G., Straeten, Vera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493652/
https://www.ncbi.nlm.nih.gov/pubmed/33013884
http://dx.doi.org/10.3389/fimmu.2020.02099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493652/
https://www.ncbi.nlm.nih.gov/pubmed/33013884
http://dx.doi.org/10.3389/fimmu.2020.02099

Ejemplares similares